HROW

Business Context and Reporting Period

Company: Transdel Pharmaceuticals, Inc. (Note: Metadata referenced "Harrow, Inc." but the filing text identifies the registrant as Transdel Pharmaceuticals, Inc.)
Reporting Period: Quarterly period ended September 30, 2010 (Form 10-Q).
Business Overview: A development-stage specialty pharmaceutical company focused on non-invasive, topically delivered products. The lead product candidate is Ketotransdel, a topical NSAID for acute pain management. The company has incurred recurring operating losses since inception and has not recognized any revenue.

Key Financial Metrics

Debt: The company holds a Senior Convertible Promissory Note of $1,000,000 issued in April 2010, with accrued interest totaling $1,036,575 as of September 30, 2010.

Material Changes vs. Prior Period

• Liquidity Decline: Cash and cash equivalents decreased from $1,589,773 at December 31, 2009, to $467,278 at September 30, 2010, a reduction of approximately $1.12 million.
• Liabilities Increase: Total liabilities increased from $1,094,873 to $1,399,775, primarily driven by the new $1 million convertible note and accrued interest.
• Operating Loss: Net loss for the nine months ended September 30, 2010, was $2.1 million, compared to $3.8 million in the same period of 2009. This improvement was largely due to a significant decrease in Research and Development (R&D) expenses as the first Phase 3 clinical trial concluded.
• R&D Expenses: R&D expenses dropped from $2.59 million (9 months 2009) to $344,900 (9 months 2010) as the primary Phase 3 study activities wound down.
• SG&A Expenses: Selling, general, and administrative expenses increased from $1.19 million to $1.75 million for the nine-month period, driven by one-time separation costs for the former CEO and increased investor relations expenses.

Outlook, Risks, and Management Commentary

• Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern. Operations beyond the fourth quarter of 2010 are dependent on securing additional financing.
• Capital Needs: The company requires additional funds to execute a second Phase 3 clinical trial, supportive safety studies, and a planned Phase 3b trial required for FDA approval of Ketotransdel. Without this funding, the company may be forced to cease operations.
• Regulatory Status: The FDA requires two adequate and well-controlled Phase 3 studies for approval. The company believes the first trial qualifies but must conduct a second trial. A Special Protocol Assessment (SPA) for the second trial design was submitted to the FDA.
• Recent Developments:
  • Received a $244,479 federal grant (Qualifying Therapeutic Discovery Project) expected by year-end 2010.
  • Appointed John N. Bonfiglio, Ph.D., as CEO and President in October 2010.
  • Entered into licensing agreements for anti-cellulite cosmeceutical products with JH Direct and Jan Marini Skin Research, though no royalties have been received to date.
• Risks: Risks include failure to obtain FDA approval, inability to raise capital, patent challenges, and reliance on third-party manufacturers and CROs.

Investor Verification Checklist

• Cash Runway: Verify if the company has secured the additional financing required to fund the second Phase 3 trial, as current cash ($467k) plus the anticipated grant ($244k) is insufficient for the full development plan.
• Debt Conversion: Review the terms of the $1 million Senior Convertible Note (7.5% interest, convertible at $1.00/share) and assess potential dilution if converted.
• CEO Transition: Confirm the impact of the new CEO appointment on the company's strategic direction and fundraising efforts.
• Phase 3 Trial Status: Verify the timeline and funding status for the second Phase 3 trial and the supportive safety studies required by the FDA.
• Going Concern Opinion: Review the most recent audit report to confirm the status of the "going concern" modification.